Thermalization and Return to Equilibrium on Finite Quantum Lattice Systems

Thermal states are the bedrock of statistical physics. Nevertheless, when and how they actually arise in closed quantum systems is not fully understood. We consider this question for systems with local Hamiltonians on finite quantum lattices. In a first step, we show that states with exponentially decaying correlations equilibrate after a quantum quench. Then we show that the equilibrium state is locally equivalent to a thermal state, provided that the free energy of the equilibrium state is sufficiently small and the thermal state has exponentially decaying correlations. As an application, we look at a related important question: When are thermal states stable against noise? In other words, if we locally disturb a closed quantum system in a thermal state, will it return to thermal equilibrium? We rigorously show that this occurs when the correlations in the thermal state are exponentially decaying. All our results come with finite-size bounds, which are crucial for the growing field of quantum thermodynamics and other physical applications.Comment: 8 pages (5 for main text and 3 for appendices); v2 is essentially the published versio

Solution of the two identical ion Penning trap final state

We have derived a closed form analytic expression for the asymptotic motion of a pair of identical ions in a high precision Penning trap. The analytic solution includes the effects of special relativity and the Coulomb interaction between the ions. The existence and physical relevance of such a final state is supported by a confluence of theoretical, experimental and numerical evidence.Comment: 5 pages and 2 figure

In-situ acoustic-based analysis system for physical and chemical properties of the lower Martian atmosphere

The Environmental Acoustic Reconnaissance and Sounding experiment (EARS), is composed of two parts: the Environmental Acoustic Reconnaissance (EAR) instrument and the Environmental Acoustic Sounding Experiment (EASE). They are distinct, but have the common objective of characterizing the acoustic environment of Mars. The principal goal of the EAR instrument is "listening" to Mars. This could be a most significant experiment if one thinks of everyday life experience where hearing is possibly the most important sense after sight. Not only will this contribute to opening up this important area of planetary exploration, which has been essentially ignored up until now, but will also bring the general public closer in contact with our most proximate planet. EASE is directed at characterizing acoustic propagation parameters, specifically sound velocity and absorption, and will provide information regarding important physical and chemical parameters of the lower Martian atmosphere; in particular, water vapor content, specific heat capacity, heat conductivity and shear viscosity, which will provide specific constraints in determining its composition. This would enable one to gain a deeper understanding of Mars and its analogues on Earth. Furthermore, the knowledge of the physical and chemical parameters of the Martian atmosphere, which influence its circulation, will improve the comprehension of its climate now and in the past, so as to gain insight on the possibility of the past presence of life on Mars. These aspect are considered strategic in the contest of its exploration, as is clearly indicated in NASA's four main objectives on "Long Term Mars Exploration Program" (http://marsweb.jpl.nasa.gov/mer/science).Comment: 16 pages including figure

Shear stress fluctuations in the granular liquid and solid phases

We report on experimentally observed shear stress fluctuations in both granular solid and fluid states, showing that they are non-Gaussian at low shear rates, reflecting the predominance of correlated structures (force chains) in the solidlike phase, which also exhibit finite rigidity to shear. Peaks in the rigidity and the stress distribution's skewness indicate that a change to the force-bearing mechanism occurs at the transition to fluid behaviour, which, it is shown, can be predicted from the behaviour of the stress at lower shear rates. In the fluid state stress is Gaussian distributed, suggesting that the central limit theorem holds. The fibre bundle model with random load sharing effectively reproduces the stress distribution at the yield point and also exhibits the exponential stress distribution anticipated from extant work on stress propagation in granular materials.Comment: 11 pages, 3 figures, latex. Replacement adds journal reference and addresses referee comment

Statistical properties of acoustic emission signals from metal cutting processes

Acoustic Emission (AE) data from single point turning machining are analysed in this paper in order to gain a greater insight of the signal statistical properties for Tool Condition Monitoring (TCM) applications. A statistical analysis of the time series data amplitude and root mean square (RMS) value at various tool wear levels are performed, �nding that ageing features can be revealed in all cases from the observed experimental histograms. In particular, AE data amplitudes are shown to be distributed with a power-law behaviour above a cross-over value. An analytic model for the RMS values probability density function (pdf) is obtained resorting to the Jaynes' maximum entropy principle (MEp); novel technique of constraining the modelling function under few fractional moments, instead of a greater amount of ordinary moments, leads to well-tailored functions for experimental histograms.Comment: 16 pages, 7 figure

Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application

Background: The ICON6 trial (ISRCTN68510403) is a phase III academic-led, international, randomized, three-arm, double-blind, placebo-controlled trial of the addition of cediranib to chemotherapy in recurrent ovarian cancer. It investigated the use of placebo during chemotherapy and maintenance (arm A), cediranib alongside chemotherapy followed by placebo maintenance (arm B) and cediranib throughout both periods (arm C). Results of the primary comparison showed a meaningful gain in progression-free survival (time to progression or death from any cause) when comparing arm A (placebo) with arm C (cediranib). As a consequence of the positive results, AstraZeneca was engaged with the Medical Research Council trials unit to discuss regulatory submission using ICON6 as the single pivotal trial. / Methods: A relatively limited level of on-site monitoring, single data entry and investigator’s local evaluation of progression were used on trial. In order to submit a license application, it was decided that (a) extensive retrospective source data verification of medical records against case report forms should be performed, (b) further quality control checks for accuracy of data entry should be performed and (c) blinded independent central review of images used to define progression should be undertaken. To assess the value of these extra activities, we summarize the impact on both efficacy and safety outcomes. / Results: Data point changes were minimal; those key to the primary results had a 0.47% error rate (36/7686), and supporting data points had a 0.18% error rate (109/59,261). The impact of the source data verification and quality control processes were analyzed jointly. The conclusion drawn for the primary outcome measure of progression-free survival between arm A and arm C was unchanged. The log-rank test p-value changed only at the sixth decimal place, the hazard ratio does not change from 0.57 with the exception of a marginal change in its upper bound (0.74–0.73) and the median progression-free survival benefit from arm C remained at 2.4 months. Separately, the blinded independent central review of progression scans was performed as a sensitivity analysis. Estimates and p values varied slightly but overall demonstrated a difference in arms, which is consistent with the initial result. Some increases in toxicity were observed, though these were generally minor, with the exception of hypertension. However, none of these increases were systematically biased toward one arm. / Conclusion: The conduct of this pragmatic, academic-sponsored trial was sufficient given the robustness of the results, shown by the results remaining largely unchanged following retrospective verification despite not being designed for use in a marketing authorization. The burden of such comprehensive retrospective effort required to ensure the results of ICON6 were acceptable to regulators is difficult to justify

Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial

Purpose: Ganetespib, a highly potent, small-molecule Heatshock protein 90 inhibitor, has potential efficacy in malignant pleural mesothelioma (MPM) via activity on critical survival pathways and known synergies with antifolates and platinum chemotherapy. We conducted a dose-escalation study to identify the maximum tolerated dose (MTD) of ganetespib in patients with chemotherapy-naïve MPM. Patients and Methods: MESO-02 (ClinicalTrials.gov: NCT01590160) was a nonrandomized, multicenter, phase Ib trial of 3-weekly ganetespib (100 mg/m2, 150 mg/m2, 200 mg/m2; days 1 and 15) with pemetrexed (500 mg/m2; day 1) and cisplatin (75 mg/m2; day 1) or carboplatin (area under concentration–time curve 5; day 1) in patients with MPM. Dose escalation was performed using the 3 + 3 design (cisplatin) and accelerated titration design (carboplatin). Secondary endpoints included best response, progression-free survival (PFS), and pharmacogenomic analyses. Results: Of 27 patients enrolled (cisplatin, n = 16; carboplatin, n = 11), 3 experienced dose-limiting toxicities: grade 3 nausea (cisplatin, n = 1; carboplatin, n = 1) and grade 2 infusion-related reaction (carboplatin, n = 1). Ganetespib's MTD was 200 mg/m2. Partial response was observed in 14 of 27 patients (52%; 61% in 23 response-evaluable patients) and 13 of 21 (62%) with epithelioid histology. At the MTD, 10 of 18 patients (56%) had partial response, 15 of 18 (83%) had disease control, and median PFS was 6.3 months (95% CI, 5.0–10.0). One responder exhibited disease control beyond 50 months. Global loss of heterozygosity was associated with shorter time to progression (HR 1.12; 95% CI, 1.02–1.24; P = 0.018). Conclusions: Ganetespib can be combined safely with pemetrexed and platinum chemotherapy to treat patients with MPM. This class of agent should be investigated in larger randomized studies